{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:26:53Z","timestamp":1783445213452,"version":"3.54.6"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.blre.2019.100642","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T21:22:23Z","timestamp":1574198543000},"page":"100642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Serological biomarkers in hemophilic arthropathy: Can they be used to monitor bleeding and ongoing progression of blood-induced joint disease in patients with hemophilia?"],"prefix":"10.1016","volume":"41","author":[{"given":"E. Carlos","family":"Rodriguez-Merchan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2019.100642_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.joca.2014.09.008","article-title":"Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study","volume":"23","author":"van Vulpen","year":"2015","journal-title":"Osteoarthr Cartil"},{"issue":"3","key":"10.1016\/j.blre.2019.100642_bb0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.rdc.2013.02.001","article-title":"Osteoarthritis: a review of strengths and weaknesses of different imaging options","volume":"39","author":"Guermazi","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.blre.2019.100642_bb0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/annrheumdis-2012-203158","article-title":"EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis","volume":"72","author":"Colebatch","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2019.100642_bb0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2516.2010.02307.x","article-title":"State-of-the-art imaging techniques for the evaluation of haemophilic arthropathy: present and future","volume":"16","author":"Doria","year":"2010","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.blre.2019.100642_bb0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/17474086.2018.1435269","article-title":"The value of HEAD-US system in detecting subclinical abnormalities in joints of patients with hemophilia","volume":"11","author":"De la Corte-Rodriguez","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.blre.2019.100642_bb0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11420-018-9604-x","article-title":"Point-of-care ultrasonography in orthopedic management of hemophilia: multiple uses of an effective tool","volume":"14","author":"De la Corte-Rodriguez","year":"2018","journal-title":"HSS J"},{"issue":"3","key":"10.1016\/j.blre.2019.100642_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.blre.2019.100642_bb0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1586\/17474086.2016.1141674","article-title":"Synovium and cartilage biomarkers in hemophilic arthropathy","volume":"9","author":"Rodriguez-Merchan","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2019.100642_bb0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/00365513.2010.493406","article-title":"Biomarkers for rheumatoid arthritis: making it personal","volume":"242","author":"Lindstrom","year":"2010","journal-title":"Scand J Clin Lab Invest Suppl"},{"issue":"2","key":"10.1016\/j.blre.2019.100642_bb0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/ar3280","article-title":"Biochemical markers of ongoing joint damage in rheumatoid arthritis\u2013current and future applications, limitations and opportunities","volume":"13","author":"Karsdal","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.blre.2019.100642_bb0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/BOR.0b013e328349a32b","article-title":"Recent advances in biomarkers in osteoarthritis","volume":"23","author":"Patra","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.blre.2019.100642_bb0060","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00002281-200309000-00020","article-title":"Biomarkers in osteoarthritis","volume":"15","author":"Garnero","year":"2003","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.blre.2019.100642_bb0065","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/art.24184","article-title":"The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy","volume":"60","author":"Jansen","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"146","key":"10.1016\/j.blre.2019.100642_bb0070","first-page":"17","article-title":"Synovial fluid alpha-melanocyte-stimulating hormone may act as a protective biomarker for primary knee osteoarthritis","volume":"27","author":"Guan","year":"2019","journal-title":"Discov Med"},{"key":"10.1016\/j.blre.2019.100642_bb0075","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.12659\/MSM.915555","article-title":"A long noncoding RNA (lncRNA)-associated competing endogenous RNA (ceRNA) network identifies eight lncRNA biomarkers in patients with osteoarthritis of the knee","volume":"25","author":"Chen","year":"2019","journal-title":"Med Sci Monit"},{"issue":"7","key":"10.1016\/j.blre.2019.100642_bb0080","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.joca.2018.12.027","article-title":"A machine learning approach to knee osteoarthritis phenotyping: data from the FNIH Biomarkers Consortium","volume":"27","author":"Nelson","year":"2019","journal-title":"Osteoarthr Cartil"},{"issue":"1","key":"10.1016\/j.blre.2019.100642_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s40634-019-0179-3","article-title":"Association between changes in molecular biomarkers of cartilage matrix turnover and changes in knee articular cartilage: a longitudinal pilot study","volume":"6","author":"Boeth","year":"2019","journal-title":"J Exp Orthop"},{"issue":"1","key":"10.1016\/j.blre.2019.100642_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1923-x","article-title":"Synovial fluid biomarkers associated with osteoarthritis severity reflect macrophage and neutrophil related inflammation","volume":"21","author":"Haraden","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.blre.2019.100642_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez199","article-title":"Biomarkers identified by serum metabolomic analysis to predict biologic treatment response in rheumatoid arthritis patients","author":"Takahashi","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2019.100642_bb0100","doi-asserted-by":"crossref","first-page":"109026","DOI":"10.1016\/j.biopha.2019.109026","article-title":"Proteomic analysis of biomarkers predicting the response to triple therapy in patients with rheumatoid arthritis","volume":"116","author":"Chen","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.blre.2019.100642_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219400","article-title":"Metabolomic approach to the exploration of biomarkers associated with disease activity in rheumatoid arthritis","volume":"14","author":"Sasaki","year":"2019","journal-title":"PLoS One"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2019.100642_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2011.02615.x","article-title":"Joint protection in haemophilia","volume":"17","author":"Rodriguez-Merchan","year":"2011","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.blre.2019.100642_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MBC.0b013e32835084dd","article-title":"Cartilage damage in the haemophilic joints: pathophysiology, diagnosis and management","volume":"23","author":"Rodriguez-Merchan","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"10.1016\/j.blre.2019.100642_bb0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.blre.2016.04.008","article-title":"Musculo-skeletal manifestations of haemophilia","volume":"30","author":"Rodriguez-Merchan","year":"2016","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.blre.2019.100642_bb0125","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.blre.2017.09.004","article-title":"Treatment of musculo-skeletal pain in haemophilia","volume":"32","author":"Rodriguez-Merchan","year":"2018","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.blre.2019.100642_bb0130","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.blre.2019.100642_bb0135","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2019.100642_bb0140","first-page":"251","article-title":"Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience","volume":"22","author":"Brackmann","year":"1992","journal-title":"Haemostasis"},{"issue":"6","key":"10.1016\/j.blre.2019.100642_bb0145","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/jth.12202","article-title":"Randomized, controlled, parallel group trial of routine prophylaxis vs. on demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)","volume":"11","author":"Manco-Johnson","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.blre.2019.100642_bb0150","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/j.1538-7836.2010.03962.x","article-title":"Blood-induced joint disease: the pathophysiology of hemophilic arthropathy","volume":"8","author":"Valentino","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2019.100642_bb0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2516.2006.01268.x","article-title":"Pathogenesis of haemophilic arthropathy","volume":"12","author":"Roosendaal","year":"2006","journal-title":"Haemophilia"},{"issue":"Suppl. 6","key":"10.1016\/j.blre.2019.100642_bb0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2516.2008.01882.x","article-title":"Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment","volume":"14","author":"Roosendaal","year":"2008","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.blre.2019.100642_bb0165","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/hae.12438","article-title":"Considerations in individualizing prophylaxis in patients with haemophilia A","volume":"20","author":"Valentino","year":"2014","journal-title":"Haemophilia"},{"issue":"13","key":"10.1016\/j.blre.2019.100642_bb0170","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2019.100642_bb0175","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jth.12317","article-title":"Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis","volume":"11","author":"Escobar","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.blre.2019.100642_bb0180","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0036-1571315","article-title":"Prophylaxis for hemophilia in the era of extended half-life factor VIII\/factor IX products","volume":"42","author":"Berntorp","year":"2016","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2019.100642_bb0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/hae.13025","article-title":"Haemophilia treatment in 2030","volume":"22","author":"Berntorp","year":"2016","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.100642_bb0190","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2516.9.s1.1.x","article-title":"When to start and when to stop primary prophylaxis in patients with severe haemophilia","volume":"9","author":"Astermark","year":"2003","journal-title":"Haemophilia"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2019.100642_bb0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2516.2010.02318.x","article-title":"Prophylaxis in the haemophilia population","volume":"16","author":"Blanchette","year":"2010","journal-title":"Haemophilia"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2019.100642_bb0200","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2516.2012.02824.x","article-title":"Clinical trial design in haemophilia","volume":"18","author":"Dimichele","year":"2012","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.blre.2019.100642_bb0205","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/hae.12936","article-title":"Potential biomarkers of haemophilic arthropathy: correlations with compatible additive magnetic resonance imaging scores","volume":"22","author":"Oldenburg","year":"2016","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.blre.2019.100642_bb0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminhematol.2015.10.005","article-title":"Advances and challenges in hemophilic arthropathy","volume":"53","author":"Wyseure","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2019.100642_bb0215","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/ijms18030601","article-title":"Review of prospects of biological fluid biomarkers in osteoarthritis","volume":"18","author":"Nguyen","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.blre.2019.100642_bb0220","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/ijms17040492","article-title":"MicroRNA-15b modulates molecular mediators of blood induced arthropathy in hemophilia mice","volume":"17","author":"Sen","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.blre.2019.100642_bb0225","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1111\/jth.13518","article-title":"Altered collagen turnover in factor VIII-deficient rats with hemophilic arthropathy identifies potential novel serological biomarkers in hemophilia","volume":"14","author":"Manon-Jensen","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.blre.2019.100642_bb0230","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2796.2008.01927.x","article-title":"Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis","volume":"263","author":"Olson","year":"2008","journal-title":"J Intern Med"},{"issue":"8","key":"10.1016\/j.blre.2019.100642_bb0235","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/art.21977","article-title":"Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis","volume":"54","author":"Kong","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"46","key":"10.1016\/j.blre.2019.100642_bb0240","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005384","article-title":"Soluble vascular cell adhesion molecular-1 is a potential biological indicator of hemophilic arthropathy","volume":"95","author":"Tseng","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.blre.2019.100642_bb0245","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1111\/hae.13196","article-title":"Serological biomarkers detect active joint destruction and inflammation in patients with haemophilic arthropathy","volume":"23","author":"Hua","year":"2017","journal-title":"Haemophilia"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19301560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19301560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:24:00Z","timestamp":1759436640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X19301560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":49,"alternative-id":["S0268960X19301560"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.100642","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological biomarkers in hemophilic arthropathy: Can they be used to monitor bleeding and ongoing progression of blood-induced joint disease in patients with hemophilia?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.100642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100642"}}